Safety immunogenicity and protective efficacy in mice of a new cell-cultured Lister smallpox vaccine candidate

被引：16

作者：

Ferrier-Rembert, Audrey ^{[4
]}

Drillien, Robert ^{[2
,3
]}

Meignier, Bernard ^{[1
]}

Garin, Daniel ^{[4
]}

Crance, Jean-Marc ^{[4
]}

机构：

[1] Sanofi Pasteur, Marcy LEtoile, France

[2] INSERM, IGBMC, U596, CNRS,UMR7104, F-67400 Illkirch Graffenstaden, France

[3] Univ Strasbourg, F-67000 Strasbourg, France

[4] CRSSA, Virol Unit, F-38702 Grenoble, France

来源：

VACCINE | 2007年 / 25卷 / 49期

关键词：

mice; smallpox vaccine; vaccinia; cowpox; smallpox; variola; immunogenicity; protection;

D O I：

10.1016/j.vaccine.2007.09.050

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

It is now difficult to manufacture the first-generation smallpox vaccine, as the process could not comply with current safety and manufacturing regulations. In this study, a candidate non-clonal second-generation smallpox vaccine developed by Sanofi-Pasteur from the Lister strain has been assessed using a cowpox virus challenge in mice. We have observed similar safety, immunogenicity and protection (from disease and death) after a short or long interval following vaccination, as well as similar virus clearance post-challenge, with the second-generation smallpox vaccine candidate as compared to the traditional vaccine used as a benchmark. (C) 2007 Elsevier Ltd. All rights reserved.

引用

页码：8290 / 8297

页数：8

共 24 条

[1] Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses [J].